Omnia SanaPlant Comparison
Goldenseal vs Bitter Melon
A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.
At a glance
Goldenseal and Bitter Melon: they share 5 indicated uses (arthritis / joint pain, bloating, indigestion, …); 2 pharmacological actions in common.
Evidence face-off — shared uses
| Condition | Goldenseal | Bitter Melon | Verdict |
|---|---|---|---|
| Arthritis / joint pain | 5/10 | 5/10 | Comparable evidence |
| Bloating | 5/10 | 1/10 | Stronger for Goldenseal |
| Indigestion | 5/10 | 1/10 | Stronger for Goldenseal |
| Inflammation (general) | 5/10 | 1/10 | Stronger for Goldenseal |
| Skin irritation | 5/10 | 1/10 | Stronger for Goldenseal |
Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.
Key Constituents
Berberine is the main antimicrobial, hypoglycaemic and hypolipidaemic constituent. Notably, whole-leaf extracts are more potent against MRSA than isolated berberine (owing to efflux-pump-inhibitory flavonoids) and show quorum-quenching, anti-virulence activity.
Now regarded as the main antidiabetic principles.
A mixture of two sterol glucosides, historically credited with the hypoglycaemic effect.
An insulin-like polypeptide of the fruit and seed.
A pyrimidine glycoside that can trigger favism in G6PD-deficient people.
Pharmacological Actions
Anti-inflammatory and astringent for inflamed mucous membranes (sore-throat gargle, mouth)
Antimicrobial (berberine) - supports skin, mucosal and gastrointestinal infections and sore throat
Anti-inflammatory and astringent for inflamed mucous membranes (sore-throat gargle, mouth)
Antidiabetic / blood-sugar lowering (improves glucose uptake and GLUT4 translocation)
Bitter digestive / stomachic (traditional use for poor digestion); mild laxative
Bitter digestive / stomachic (traditional use for poor digestion); mild laxative
Bitter digestive / stomachic (traditional use for poor digestion); mild laxative
Traditional & Indicated Uses
inferred from anti-inflammatory action
Digestive / gastrointestinal support (traditional for dyspepsia and ulcers)
Antimicrobial (berberine) - supports skin, mucosal and gastrointestinal infections and sore throat; Topical for skin infections and irritation - whole-leaf extract is active in vitro against methicillin-resistant Staphylococcus aureus (MRSA)
inferred from anti-inflammatory action
inferred from anti-inflammatory action
Anti-inflammatory and astringent for inflamed mucous membranes (sore-throat gargle, mouth); Antimicrobial (berberine) - supports skin, mucosal and gastrointestinal infections and sore throat
inferred from bitter-tonic action
inferred from anti-inflammatory action
Antidiabetic / blood-sugar lowering (improves glucose uptake and GLUT4 translocation)
inferred from anticancer action
inferred from anti-inflammatory action
inferred from antidiabetic action
inferred from anti-inflammatory action
Safety, Cautions & Contraindications
Contraindicated in pregnancy and breastfeeding: berberine crosses the placenta and into milk and can cause or worsen newborn jaundice (risk of kernicterus); do not give to infants.
Berberine strongly inhibits drug-metabolising enzymes (especially CYP3A4 and CYP2D6), so it can raise the blood levels of many medicines - a significant herb-drug-interaction risk. In a screen of commercial herbal products, goldenseal was among the most potent CYP2D6 inhibitors and also inhibited CYP3A4. High doses have shown possible liver, nerve and photo-toxicity.
Avoid in pregnancy: bitter melon can stimulate the uterus and has been associated with miscarriage; also avoid during breastfeeding.
Strong blood-sugar-lowering action: used with insulin or other diabetes medicines it can cause hypoglycaemia - monitor blood glucose and seek medical advice.
People with glucose-6-phosphate dehydrogenase (G6PD) deficiency should avoid the seeds, which contain vicine and can cause favism (haemolytic anaemia). Excessive intake may cause abdominal pain and diarrhoea.
External Ids
Botanical Description
Low, woodland perennial herb rising from a knotted, bright yellow rhizome with wiry yellow roots. Each stem bears two ragged, palmately lobed, maple-like leaves and a single small, inconspicuous greenish-white flower, followed by a raspberry-like cluster of red berries.[1]
Climbing or trailing annual vine (Cucurbitaceae) that climbs by simple tendrils, typically 2-5 m long. Leaves are alternate, long-stalked and palmately lobed with 5-7 deep, toothed lobes. Flowers are small, yellow and five-petalled, male and female flowers separate on the same plant. The fruit is an oblong, warty-skinned gourd that ripens from green to orange-yellow and splits open to reveal seeds coated in a bright red aril; the unripe green fruit is the part used medicinally and as food.
Habitat
Grows in rich, shaded deciduous woodland with humus-rich soil; native to eastern North America, now scarce in the wild due to overharvesting and largely supplied by cultivation.[1]
Likely native to tropical Asia (possibly the Indian subcontinent), now widely cultivated across tropical and subtropical Asia, Africa, the Caribbean and increasingly the Americas as a vegetable and medicinal crop; needs warmth, full sun and a trellis or support to climb.[11]
Harvesting
The rhizome and root are dug in autumn from plants at least three to four years old, when berberine content is highest, then cleaned and dried; because wild populations are depleted, cultivated or sustainably sourced material is strongly preferred, and careful identification against the toxic mayapple and bloodroot, which share its woodland habitat, is essential before any wild-harvesting.[1]
The fruit is harvested unripe, while still green and firm, before it yellows and splits, for use as a vegetable and in traditional antidiabetic preparations; leaves are also traditionally gathered.[11]
Traditional Uses
Goldenseal root has a Native American and, after adoption by Eclectic physicians, wider North American tradition as a bitter tonic and antimicrobial remedy for mucous-membrane infections, sore throat, digestive upset and topical skin infections, directly reflecting its high berberine content.[1]
Bitter melon has a long history in Asian, African and Caribbean traditional medicine as a bitter digestive tonic and mild laxative, and most notably as a remedy for diabetes and its complications; this traditional antidiabetic use is now the most scientifically supported of its properties, with numerous studies on its blood-glucose- and lipid-lowering effects.[4, 11]
Preparations
Dried rhizome and root simmered in water as a traditional bitter antimicrobial tea, or used as a gargle for sore throat.
Tincture 1:10 in 60% ethanol of the dried rhizome and root, 2-4 ml three times daily per the WHO monograph Rhizoma Hydrastis. Educational reference only, not a prescription.
Extract standardised to berberine/hydrastine content, taken as capsules; whole-leaf extracts have shown stronger antimicrobial activity than isolated berberine in some studies.
Dosage
The WHO monograph on Rhizoma Hydrastis gives a daily dose of 0.5-1.0 g of the dried rhizome and root three times, or taken as a decoction; a 1:1 liquid extract in 60% ethanol at 0.3-1.0 mL three times; or a 1:10 tincture in 60% ethanol at 2-4 mL three times. For short-term use only, given goldenseal's potent CYP-enzyme inhibition and its contraindication in pregnancy. Educational reference only, not a prescription.
Clinical trials studying bitter melon for blood-sugar support have used standardised fruit extract or juice preparations taken daily over several weeks; dosing varies by product. Because it can lower blood glucose, monitor levels closely if combining with diabetes medication. Educational reference only, not a prescription.
References
Drug Class Interactions
Lookalikes Review
Dangerous Lookalikes
Not documented
References & Sources
- Mandal, S.K., Maji, A.K., Mishra, S.K., Ishfaq, P.M., Devkota, H.P., Silva, A.S. and Das, N (2020) 'Goldenseal (Hydrastis canadensis L.) and its active constituents: A critical review of their efficacy and toxicological issues', Pharmacological Research. doi:10.1016/j.phrs.2020.105085 Randomized trial
https://doi.org/10.1016/j.phrs.2020.105085 - Corn, J., Tibbitts, D., Ito, H., Schafer, M. and Vasilevsky, N (2021) 'Effects of Hydrastis Canadensis, Commiphora Habessinica, Phytolacca Americana, and Echinacea Purpurea on Bacterial Growth', Alternative Therapies in Health and Medicine, 27(4), pp. 24-27. Preclinical
https://scholar.google.com/scholar?q=Effects%20of%20Hydrastis%20Canadensis%2C%20Commiphora%20Habessinica%2C%20Phytolacca%20Americana%2C%20and%20Echinacea%20Purpurea%20on%20Bacterial%20Growth - Ettefagh, K.A., Burns, J.T., Junio, H.A., Kaatz, G.W. and Cech, N.B (2010) 'Goldenseal (Hydrastis canadensis L.) extracts synergistically enhance the antibacterial activity of berberine via efflux pump inhibition', Planta Medica, 77(8), pp. 835-840. doi:10.1055/s-0030-1250606 Preclinical
https://doi.org/10.1055/s-0030-1250606 - Cech, N.B., Junio, H.A., Ackermann, L.W., Kavanaugh, J.S. and Horswill, A.R (2012) 'Quorum quenching and antimicrobial activity of goldenseal (Hydrastis canadensis) against methicillin-resistant Staphylococcus aureus (MRSA)', Planta Medica, 78(14), pp. 1556--1561. doi:10.1055/s-0032-1315042 Traditional / reference
https://doi.org/10.1055/s-0032-1315042 - Mahady, G.B., Pendland, S.L., Stoia, A. and Chadwick, L.R (2003) 'In vitro susceptibility of Helicobacter pylori to isoquinoline alkaloids from Sanguinaria canadensis and Hydrastis canadensis', Phytotherapy Research, 17(3), pp. 217-221. doi:10.1002/ptr.1108 Preclinical
https://doi.org/10.1002/ptr.1108 - Junio, H.A., Sy-Cordero, A.A., Ettefagh, K.A., Burns, J.T., Micko, K.T., Graf, T.N., Richter, S.J., Cannon, R.E., Oberlies, N.H. and Cech, N.B (2011) 'Synergy-directed fractionation of botanical medicines: a case study with goldenseal (Hydrastis canadensis)', Journal of Natural Products, 74(7), pp. 1621-1629. doi:10.1021/np200336g Preclinical
https://doi.org/10.1021/np200336g - Britton, E.R., Kellogg, J.J., Kvalheim, O.M. and Cech, N.B (2017) 'Biochemometrics to Identify Synergists and Additives from Botanical Medicines: A Case Study with Hydrastis canadensis (Goldenseal)', Journal of Natural Products, 81(3), pp. 484-493. doi:10.1021/acs.jnatprod.7b00654 Preclinical
https://doi.org/10.1021/acs.jnatprod.7b00654 - Leyte-Lugo, M., Britton, E.R., Foil, D.H., Brown, A.R., Todd, D.A., Rivera-Chavez, J., Oberlies, N.H. and Cech, N.B (2017) 'Secondary Metabolites from the Leaves of the Medicinal Plant Goldenseal (Hydrastis canadensis)', Phytochemistry Letters, 20, pp. 54-60. doi:10.1016/j.phytol.2017.03.012 Preclinical
https://doi.org/10.1016/j.phytol.2017.03.012 - Gurley, B.J., Swain, A., Hubbard, M.A., Hartsfield, F., Thaden, J., Williams, D.K., Gentry, W.B. and Tong, Y (2007) 'Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo', Clinical Pharmacology and Therapeutics, 83(1), pp. 61-69. doi:10.1038/sj.clpt.6100222 Randomized trial
https://doi.org/10.1038/sj.clpt.6100222 - Wallace, E.D., Oberlies, N.H., Cech, N.B. and Kellogg, J.J (2018) 'Detection of adulteration in Hydrastis canadensis (goldenseal) dietary supplements via untargeted mass spectrometry-based metabolomics', Food and Chemical Toxicology, 120, pp. 439-447. doi:10.1016/j.fct.2018.07.033 Preclinical
https://doi.org/10.1016/j.fct.2018.07.033 - Douglas, J.A., Follett, J.M., Parmenter, G.A., Sansom, C.E., Perry, N.B. and Littler, R.A (2010) 'Seasonal variation of biomass and bioactive alkaloid content of goldenseal, Hydrastis canadensis', Fitoterapia, 81(7), pp. 925-928. doi:10.1016/j.fitote.2010.06.006 Preclinical
https://doi.org/10.1016/j.fitote.2010.06.006 - Singh, S., Pathak, N., Fatima, E. and Negi, A.S (2021) 'Plant isoquinoline alkaloids: Advances in the chemistry and biology of berberine', European Journal of Medicinal Chemistry. doi:10.1016/j.ejmech.2021.113839 Preclinical
https://doi.org/10.1016/j.ejmech.2021.113839 - World Health Organization (2007) 'Rhizoma Hydrastis'. Available at: https://iris.who.int/items/6418d8af-5200-4e6b-9bf5-004f3aa62a37 Traditional / reference
https://iris.who.int/items/6418d8af-5200-4e6b-9bf5-004f3aa62a37 - Sevior, D.K., Hokkanen, J., Tolonen, A., Abass, K., Tursas, L., Pelkonen, O. and Ahokas, J.T (2010) 'Rapid screening of commercially available herbal products for the inhibition of major human hepatic cytochrome P450 enzymes using the N-in-one cocktail', Xenobiotica, 40(4), pp. 245--254. doi:10.3109/00498251003592683 Preclinical
https://doi.org/10.3109/00498251003592683 - Gurley, B.J., Gardner, S.F., Hubbard, M.A., Williams, D.K., Gentry, W.B., Khan, I.A. and Shah, A (2005) 'In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes', Clinical Pharmacology and Therapeutics, 77(5), pp. 415-426. doi:10.1016/j.clpt.2005.01.009 Randomized trial
https://doi.org/10.1016/j.clpt.2005.01.009 - McDonald, M.G., Tian, D.D., Thummel, K.E., Paine, M.F. and Rettie, A.E (2020) 'Modulation of major human liver microsomal cytochromes P450 by component alkaloids of goldenseal: time-dependent inhibition and allosteric effects', Drug Metabolism and Disposition, 48(10), pp. 1018-1027. doi:10.1124/dmd.120.091041 Preclinical
https://doi.org/10.1124/dmd.120.091041 - Guo, J., Chen, H., Zhang, X., Lou, W., Zhang, P., Qiu, Y., Zhang, C., Wang, Y. and Liu, W.J (2021) 'The effect of berberine on metabolic profiles in type 2 diabetic patients: a systematic review and meta-analysis of randomized controlled trials', Oxidative Medicine and Cellular Longevity, 2021, pp. 2074610. doi:10.1155/2021/2074610 Meta-analysis / review
https://doi.org/10.1155/2021/2074610 - Forest Farming (Cooperative Extension) 'Goldenseal (Hydrastis canadensis L.)'. Available at: https://forest-farming.extension.org/goldenseal-hydrastis-canadensis-l/ Traditional / reference
https://forest-farming.extension.org/goldenseal-hydrastis-canadensis-l/ - Frasca, T. and Brett, A.S. and Yoo, S.D (1997) 'Mandrake toxicity. A case of mistaken identity', Archives of Internal Medicine, 157(17), pp. 2007-9. doi:10.1001/archinte.157.17.2007 Clinical study
https://doi.org/10.1001/archinte.157.17.2007 - North Carolina Extension Gardener Plant Toolbox 'Sanguinaria canadensis (Bloodroot)'. Available at: https://plants.ces.ncsu.edu/plants/sanguinaria-canadensis/ Traditional / reference
https://plants.ces.ncsu.edu/plants/sanguinaria-canadensis/
- Kim, S.K., Jung, J., Jung, J.H., Yoon, N. and others (2020) 'Hypoglycemic efficacy and safety of Momordica charantia (bitter melon) in patients with type 2 diabetes mellitus', Complementary Therapies in Medicine, 52, pp. 102524. doi:10.1016/j.ctim.2020.102524 Randomized trial
https://doi.org/10.1016/j.ctim.2020.102524 - Fang, E.F., Froetscher, L., Scheibye-Knudsen, M., Bohr, V.A. and others (2019) 'Emerging Antitumor Activities of the Bitter Melon (Momordica charantia)', Current Protein & Peptide Science, 20(3), pp. 296-301. doi:10.2174/1389203719666180622095800 Meta-analysis / review
https://doi.org/10.2174/1389203719666180622095800 - Raina, K., Kumar, D. and Agarwal, R (2016) 'Promise of bitter melon (Momordica charantia) bioactives in cancer prevention and therapy', Seminars in Cancer Biology, 40-41, pp. 116-129. doi:10.1016/j.semcancer.2016.07.002 Meta-analysis / review
https://doi.org/10.1016/j.semcancer.2016.07.002 - Basch, E., Gabardi, S. and Ulbricht, C (2003) 'Bitter melon (Momordica charantia): a review of efficacy and safety', American Journal of Health-System Pharmacy, 60(4), pp. 356-359. doi:10.1093/ajhp/60.4.356 Meta-analysis / review
https://doi.org/10.1093/ajhp/60.4.356 - Bora, A.F.M., Kouame, K.J.E., Li, X., Liu, L. and others (2023) 'New insights into the bioactive polysaccharides, proteins, and triterpenoids isolated from bitter melon (Momordica charantia) and their relevance for nutraceutical and food application: A review', International Journal of Biological Macromolecules, 231, pp. 123173. doi:10.1016/j.ijbiomac.2023.123173 Meta-analysis / review
https://doi.org/10.1016/j.ijbiomac.2023.123173 - Soo May, L., Sanip, Z., Ahmed Shokri, A., Abdul Kadir, A. and others (2018) 'The effects of Momordica charantia (bitter melon) supplementation in patients with primary knee osteoarthritis: A single-blinded, randomized controlled trial', Complementary Therapies in Clinical Practice, 32, pp. 181-186. doi:10.1016/j.ctcp.2018.06.012 Randomized trial
https://doi.org/10.1016/j.ctcp.2018.06.012 - Elekofehinti, O.O., Ariyo, E.O., Akinjiyan, M.O., Olayeriju, O.S. and others (2018) 'Potential use of bitter melon (Momordica charantia) derived compounds as antidiabetics: In silico and in vivo studies', Pathophysiology, 25(4), pp. 327-333. doi:10.1016/j.pathophys.2018.05.003 Preclinical
https://doi.org/10.1016/j.pathophys.2018.05.003 - Leung, L., Birtwhistle, R., Kotecha, J., Hannah, S. and others (2009) 'Anti-diabetic and hypoglycaemic effects of Momordica charantia (bitter melon): a mini review', British Journal of Nutrition, 102(12), pp. 1703-1708. doi:10.1017/S0007114509992054 Meta-analysis / review
https://doi.org/10.1017/S0007114509992054 - Krawinkel, M.B. and Keding, G.B (2006) 'Bitter gourd (Momordica charantia): A dietary approach to hyperglycemia', Nutrition Reviews, 64(7 Pt 1), pp. 331-337. doi:10.1301/nr.2006.jul.331-337 Meta-analysis / review
https://doi.org/10.1301/nr.2006.jul.331-337 - Fang, E.F. and Ng, T.B (2011) 'Bitter gourd (Momordica charantia) is a cornucopia of health: a review of its credited antidiabetic, anti-HIV, and antitumor properties', Current Molecular Medicine, 11(5), pp. 417-436. doi:10.2174/156652411795976583 Meta-analysis / review
https://doi.org/10.2174/156652411795976583 - Cicek, S.S (2022) 'Momordica charantia L. - Diabetes-Related Bioactivities, Quality Control, and Safety Considerations', Frontiers in Pharmacology. doi:10.3389/fphar.2022.904643 Traditional / reference
https://doi.org/10.3389/fphar.2022.904643 - WebMD (n.d.) 'Bitter Melon: Overview, Uses, Side Effects, Precautions, Interactions'. Available at: https://www.webmd.com/vitamins/ai/ingredientmono-795/bitter-melon Traditional / reference
https://www.webmd.com/vitamins/ai/ingredientmono-795/bitter-melon - Yedjou, C.G., Grigsby, J., Mbemi, A., Nelson, D., Mildort, B., Latinwo, L. and Tchounwou, P.B (2023) 'The Management of Diabetes Mellitus Using Medicinal Plants and Vitamins', International Journal of Molecular Sciences. doi:10.3390/ijms24109085 Randomized trial
https://doi.org/10.3390/ijms24109085 - Kim, S.K., Jung, J., Jung, J.H., Yoon, N., Kang, S.S., Roh, G.S. and Hahm, J.R (2020) 'Hypoglycemic efficacy and safety of Momordica charantia (bitter melon) in patients with type 2 diabetes mellitus', Complementary Therapies in Medicine, 52, pp. 102524. doi:10.1016/j.ctim.2020.102524 Randomized trial
https://doi.org/10.1016/j.ctim.2020.102524 - Zhang, X., Zhao, Y., Song, Y. and Miao, M (2024) 'Effects of Momordica charantia L. supplementation on glycemic control and lipid profile in type 2 diabetes mellitus patients: a systematic review and meta-analysis of randomized controlled trials', Heliyon, 10(10), pp. e31126. doi:10.1016/j.heliyon.2024.e31126 Meta-analysis / review
https://doi.org/10.1016/j.heliyon.2024.e31126
Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.